Chemoradiation in Esophagogastric Junction Cancer

For decades, primary surgery and radiotherapy (RT) alone were two treatment options for potentially curable esophageal cancer. Outcomes were poor, with most patients developing recurrent disease with associated morbidity and mortality. Both treatment options evolved over time as a result of better staging [1–3] and improved surgical [4–6] and radiation techniques [7, 8]. Furthermore, the addition of chemotherapy (CT) to RT and the combination of surgical and nonsurgical approaches were important developments in the treatment of esophageal cancer. However, due to a lack of high-quality evidence, treatment of choice for esophageal cancer still remains controversial. Institutional preferences and clinical opinions still dominate the applied treatments. In this chapter, we give an overview of the role of chemoradiotherapy (CRT) in the treatment of adenocarcinomas (AC) of the distal esophagus and esophagogastric junction (EGJ).